Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101/Anselamimab in AL Amyloidoma
NCT07615270Phase 1Not yet recruiting
- Sponsor
- Stanford University
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anselamimab in amyloid light chain amyloidosis, sponsored by Stanford University. Primary endpoint: Change From Baseline in Amyloid Target Lesion Size at 72 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
anselamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT07615270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615270.